CDEK
← All drugs Report issue

sapanisertib

Small moleculeexperimental

Sapanisertib is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2. — Wikipedia

Clinical trial activity

51 trials · 31 clinical orgs · 0 marketing orgs

Phase 1
26
Phase 2
30
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2005 (NCT00229437)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21
Mol. weight
309.33 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • ink128
  • ink-128
  • ink-128
  • mln0128
  • mln0128
  • mln0128
  • mln-0128
  • mln-0128
  • sapanisertib
  • sapanisertib
  • sapanisertib
  • tak-128
  • tak-228
  • tak-228

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06811116Phase 1/Phase 2 (Phase 2)May 16, 2025National Cancer Institute (NCI), University of Pittsburgh
NCT06463028Phase 2Dec 31, 2024Faeth Therapeutics, GOG Foundation, Inc.
NCT05275673Phase 2Apr 15, 2022Calithera Biosciences
NCT05022394Phase 1/Phase 2 (Phase 2)Feb 18, 2021National Cancer Institute (NCI), University of Texas at Houston
NCT04267913Phase 2Sep 5, 2020National Cancer Institute (NCI), Southwest Oncology Group
NCT04479306Phase 1Jun 18, 2020University of Texas at Houston
NCT04250545Phase 1Mar 13, 2020City of Hope National Medical Center, National Cancer Institute (NCI)
NCT03648489Phase 2Sep 30, 2018Imperial College London, North Eastern Germany Society of Gynaecologic Oncology, Takeda
NCT03745911Phase 2May 4, 2018Associació per a la Recerca Oncologica, Spain, Pivotal S.L., Takeda, Universidad Autonoma de Barcelona
NCT03205891Phase 1Mar 31, 2018Takeda, University of Texas at Houston
NCT03430882Phase 1Mar 12, 2018Takeda, University of Texas at Houston
NCT03370302Phase 1Jan 17, 2018Millennium Pharmaceuticals
NCT03193853Phase 2Jul 5, 2017Baylor University, Takeda
NCT03154294Phase 1Jul 1, 2017Avera Cancer Institute, Avera Health
NCT03017833Phase 1Jun 1, 2017Takeda, University of Texas at Houston
NCT03097328Phase 2May 14, 2017Harvard University, Millennium Pharmaceuticals
NCT02988986Phase 2Apr 24, 2017Methodist Cancer Center, Houston, Texas, Millennium Pharmaceuticals
NCT02619669Phase 1Apr 20, 2017Dartmouth University
NCT06390865Phase 2Mar 12, 2017ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
NCT06385496Phase 2Mar 12, 2017ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Showing 20 of 51 trials
Page 1 / 3

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Millennium PharmaceuticalsFor profit191222010
National Cancer Institute (NCI)Government161432014
TakedaFor profit12222005
University of Texas at HoustonAcademic/Hospital8722014
ECOG-ACRIN Cancer Research GroupAcademic/Hospital4012015
Harvard UniversityAcademic/Hospital4322014
Cornell UniversityAcademic/Hospital2112014
Associació per a la Recerca Oncologica, SpainAcademic/Hospital1112018
Avera Cancer InstituteAcademic/Hospital1012017
Avera HealthAcademic/Hospital1112017
Baylor UniversityAcademic/Hospital1112017
Big Ten Cancer Research ConsortiumAcademic/Hospital1112016
Calithera BiosciencesFor profit1112022
City of Hope National Medical CenterAcademic/Hospital1012020
Dartmouth UniversityAcademic/Hospital1112017
European Network of Individualized Treatment in Endometrial CancerAcademic/Hospital1012016
European Network of Translational Research in Ovarian CancerAcademic/Hospital1012016
Faeth TherapeuticsFor profit1112024
GOG Foundation, Inc.Academic/Hospital1012024
Imperial College LondonAcademic/Hospital1112018
31 organizations
Page 1 / 2